Log in to search using one of your social media accounts:

 

Monthly Injected Schizophrenia Drug Has Modest Metabolic Effects Monthly Injected Schizophrenia Drug Has Modest Metabolic Effects
Patients show small changes in weight and metabolic parameters from long-term treatment with injectable aripiprazole lauroxil (AL), new research shows.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Overdoses with aripiprazole: signs, symptoms and outcomes in 239 exposures reported to the Danish Poison Information Center - Christensen AP, Boegevig S, Christensen MB, Petersen KM, Dalhoff KP, Petersen TS.
The aim of this study was to characterize the clinical signs and symptoms of exposures to aripiprazole overdoses. We retrospectively identified all aripiprazole exposures reported to the Danish Poisons Information Center (DPIC) from June 2007 to May 2015. ... (Source: SafetyLit)
Source: SafetyLit - September 9, 2017 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

ReCor Medical adds another $12m for trial of Paradise renal denervation device
ReCor Medical last week added a $12 million contribution from Otsuka Pharmaceutical (TYO:4578) to the $10 million it raised from the Japanese conglomerate last year for a clinical trial of its Paradise renal denervation device for treating hypertension, ReCor president & CEO Andrew Weiss told MassDevice.com this morning. In May 2016 Otsuka participated in a strategic investment of an unspecified amount; Weiss told us that that round and the $12 million debt financing added last week are earmarked for the Radiance-HTN efficacy study of the Paradise device, which is designed to use ultrasoun...
Source: Mass Device - August 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Funding Roundup Wall Street Beat Hypertension ReCor Medical Source Type: news

Injectable, extended-release bipolar drug wins FDA nod
Otsuka Pharmaceutical (TYO:4578) and Lundbeck said last week that its extended-release injectable aripiprazole suspension, Abilify Maintena, won FDA approval as a maintenance monotherapy for adults with bipolar I disorder. The once-monthly intramuscular formulation was created by Otsuka and co-developed and commercialized with Lundbeck, the companies reported. Get the full story at our sister site, Drug Delivery Business News. The post Injectable, extended-release bipolar drug wins FDA nod appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - July 31, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Food & Drug Administration (FDA) Neurological Pharmaceuticals Regulatory/Compliance Wall Street Beat Lundbeck Otsuka Pharmaceutical Source Type: news

FDA Approves Long-acting Injectable for Bipolar Disorder FDA Approves Long-acting Injectable for Bipolar Disorder
The FDA has approved extended-release injectable aripiprazole for maintenance monotherapy for bipolar disorder in adults.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 31, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena ® (aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 28, 2017 Category: Drugs & Pharmacology Source Type: news

Addition of Aripiprazole Ups Major Depressive Disorder Remission
Small increased likelihood of remission at 12 weeks in patients with major depressive disorder (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - July 12, 2017 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Nursing, Pharmacy, Psychiatry, Journal, Source Type: news

For Treatment-Resistant Depression, Add an Antipsychotic or Switch Antidepressants? (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM For patients with depression unresponsive to antidepressants, adding the antipsychotic aripiprazole seems modestly better than switching to the antidepressant bupropion, a JAMA study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 12, 2017 Category: Primary Care Source Type: news

Study compares switching meds vs. an additional med for patients unresponsive to an antidepressant
(The JAMA Network Journals) Among patients unresponsive to an antidepressant medication, adding the antipsychotic aripiprazole modestly increased the likelihood of remission from depression compared to switching to the antidepressant bupropion, according to a study published by JAMA. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - July 11, 2017 Category: International Medicine & Public Health Source Type: news

Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis Antipsychotics Have Side Effects, Limited Value in Pediatric Psychosis
For children and adolescents with first-episode psychosis, the second generation antipsychotics quetiapine extended release and aripiprazole have equivalent efficacy, but different side effect profiles, according to a head-to-head comparison.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

FDA Approves Longer-Acting Aripiprazole for Schizophrenia FDA Approves Longer-Acting Aripiprazole for Schizophrenia
The FDA has approved a 2-month dose of aripiprazole lauroxil extended-release injectable suspension for the treatment of schizophrenia.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 6, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news

FDA Approves Two-Month Aristada for Treatment of Schizophrenia
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 6, 2017 Category: Drugs & Pharmacology Source Type: news

Otsuka, Proteus resubmit FDA application for novel drug-device combination
One year after the FDA declined to approve Proteus Digital Health and Otsuka's new sensor-embedded formulation of Otsuka's antipsychotic drug Abilify, the companies are giving it another shot, resubmitting the application with additional information. (Source: mobihealthnews)
Source: mobihealthnews - May 23, 2017 Category: Information Technology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 23, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. Philips picks up airway clearance device dev RespirTech Royal Philips said today it inked a deal to acquire airway clearance solution developer RespirTech for an undisclosed amount. St. Paul, Minn.-based RespirTech was founded ...
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said today that the FDA accepted its resubmitted new drug application for their “smart pill”. The drug-device product combines Abilify and a Proteus ingestible sensor in a single tablet. The FDA is slated to make a decision on the NDA resubmission in the 4th quarter this year. Get the full story at our sister site, Drug Delivery Business News. The post Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 23, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Otsuka Pharmaceutical Proteus Digital Health Source Type: news

aripiprazole (Abilify, Abilify Maintena, Aristrada)
Title: aripiprazole (Abilify, Abilify Maintena, Aristrada)Category: MedicationsCreated: 2/17/2004 12:00:00 AMLast Editorial Review: 5/1/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 1, 2017 Category: Drugs & Pharmacology Source Type: news

Improve Your Mood With Turmeric Root (Curcumin)
"Dr. Sears," C.R. asked me, "I know curcumin is good for treating a lot of things, but can it improve someone's mood?" This morning, one of the women on my staff, C.R., came into my office to talk to me about her 15-year-old son. He'd been irritable and moody and sleeping a lot lately. Most mornings, he'd miss the bus to school and then stress about being late. But today, he was up on time with his backpack packed and a smile on his face. C.R. even heard him whistling in the shower! And he was at the bus stop 10 minutes early. C. R. started taking curcumin supplements a few weeks ago. She ha...
Source: Al Sears, MD Natural Remedies - March 21, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Abilify (Aripiprazole) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 21, 2017 Category: Drugs & Pharmacology Source Type: news

We Must Fight Rhino Poaching With Science And Dismiss Superstition
A recent story about poachers breaking into the zoo in Paris and killing a rhino to saw off its horn has led to Czech and Belgian zookeepers pre-emptively sawing off the horns of their rhinos in captivity to thwart potential poachers. That sort of supply-reduction thinking will work just as effectively as fumigating illicit cocaine crops and banning assault weapons. You cannot repeal the law of supply and demand. So long as there is demand for rhino horns, cocaine, and assault weapons, someone will step up to supply them. The demand for cocaine and assault weapons seems easy to understand. But does everybody know why poach...
Source: Science - The Huffington Post - March 16, 2017 Category: Science Source Type: news

Aristada (Aripiprazole Lauroxil Extended-release Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 13, 2017 Category: Drugs & Pharmacology Source Type: news

The drug that makes you binge on sex, gambling and food
The antipsychotic drug Abilify, used to treat schizophrenia and depression, is at the center of hundreds of lawsuits over claims that side effects included gambling and binge shopping (Source: the Mail online | Health)
Source: the Mail online | Health - February 17, 2017 Category: Consumer Health News Source Type: news

Once-Monthly Aripiprazole Effective in Bipolar Disorder Once-Monthly Aripiprazole Effective in Bipolar Disorder
The once-monthly injection, currently available for schizophrenia, is seen as a potentially important tool to prevent nonadherence.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Aripiprazole Tablets (Aripiprazole Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 13, 2017 Category: Drugs & Pharmacology Source Type: news

Aripiprazole Oral Solution (Aripiprazole Oral Solution) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 13, 2017 Category: Drugs & Pharmacology Source Type: news

Odds of early death in Alzheimer's patients nearly doubles after taking antipsychotic drugs
(NaturalNews) Alzheimer’s patients who take antipsychotic drugs have a significantly increased risk of dying early compared to those who don’t, new research out of Finland has found. An in-depth analysis of nearly 58,000 people diagnosed with Alzheimer’s disease between 2005 and 2011 found that those who take popular antipsychotics like Abilify (aripiprazole) or Risperdeal (risperidone)... (Source: NaturalNews.com)
Source: NaturalNews.com - January 4, 2017 Category: Consumer Health News Source Type: news

Florida, other states settle with Bristol-Myers Squibb over antipsychotic drug
Florida will get a piece of a $19.5 million settlement with Bristol-Myers Squibb Co. in a case alleging the drug company improperly marketed Abilify. According to a multi-state complaint filed by Florida Attorney General Pam Bondi and attorneys general in 42 other states and the District of Columbia, Bristol-Myers Squibb (NYSE: BMY) promoted the antipsychotic drug for treating elderly patients and children for uses that were not approved by the U.S. Food& Drug Administration. See the final judgment… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 12, 2016 Category: Biotechnology Authors: Margie Manning Source Type: news

Morning Break: Heroin Deadlier than Guns; Abilify Fines; Interstate Insurance Flops
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - December 9, 2016 Category: Respiratory Medicine Source Type: news

Bristol-Myers Squibb to pay $19.5 million over Abilify marketing
Bristol-Myers Squibb on Thursday struck a $19.5 million settlement to resolve claims by 43 states, that it marketed an antipsychotic drug to elderly patients and children for unapproved conditions. Massachusetts Attorney General Maura Healey said in a statement that more than $400,000 of the funds would go to the state. BMS (NYSE: BMY), which is headquartered in New York City and has a manufacturing facility in Devens, Mass., was accused of engaging in unfair and deceptive trade practices t hrough… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 9, 2016 Category: Biotechnology Authors: Max Stendahl Source Type: news

Effect of aripiprazole augmentation for the depressive symptoms changes with progression of Lewy body disease - Iwamoto K, Fujishiro H, Ozaki N.
This report shows that aripiprazol... (Source: SafetyLit)
Source: SafetyLit - November 25, 2016 Category: Global & Universal Tags: Age: Elder Adults Source Type: news

UCLA awarded grant to study depression in older adults
More than half of older adults who are treated for depression find that eventually their treatments are no longer effective. When depression persists, these people are at greater risk of accelerated aging, declining mental health and even suicide.To help address this, UCLA and four other institutions have been awarded a $13.9 million grant to evaluate treatment strategies for older adults with depression who have not responded to medications. UCLA psychiatry professor Dr. Helen Lavretsky will serve as principal investigator on this new study.“No more than 30 to 40 percent of people respond to first-line treatments,&r...
Source: UCLA Newsroom: Health Sciences - September 30, 2016 Category: Universities & Medical Training Source Type: news

Abilify Maintena (Aripiprazole Extended-Release Injectable Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 7, 2016 Category: Drugs & Pharmacology Source Type: news

Aripiprazole in the treatment of obsessive compulsive disorder and aggressive behaviors in a child with Prader Willi syndrome: a case report - Akca OF, Yilmaz S.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - August 19, 2016 Category: Global & Universal Tags: Age: Infants and Children Source Type: news

A new method cuts the cost of drug-building chemicals
EPFL (École polytechnique fédérale de Lausanne) scientists design a new method to cheaply produce some of the most important chemical compounds in the pharmaceutical industry - the amines. The amines are one of the most important classes of chemical compounds today. Amines that contain a ring-like structure - called an "aryl" group - are used widely in pharmaceuticals, such as the top-selling drugs Abilify, Crestor, Gleevec, and Lidoderm. (Source: World Pharma News)
Source: World Pharma News - August 12, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Aripiprazole reduces severity of tics in children with Tourette's disorder
(Mary Ann Liebert, Inc./Genetic Engineering News) A meta-analysis of clinical trials evaluating the effectiveness of aripiprazole for the treatment of Tourette's disorder (TD) in children and adolescents showed a significantly greater overall improvement in total tics and tic severity from pretreatment to post-treatment for the aripiprazole compared to the placebo group. The drug was safe, with drowsiness, nausea, and headache being the most common adverse effects, according to the study published in Journal of Child and Adolescent Psychopharmacology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 20, 2016 Category: Global & Universal Source Type: news

Aripiprazole for autism spectrum disorders (ASD)
Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder - not otherwise specified (PDD-NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third-generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011). To assess the safety and efficacy of aripiprazole as medication treatm...
Source: Current Awareness Service for Health (CASH) - July 12, 2016 Category: Consumer Health News Source Type: news

Improving Drug Trials: Lessons Learned From AripiprazoleImproving Drug Trials: Lessons Learned From Aripiprazole
Dr Lieberman discusses the FDA's recent warning about the side effects of aripiprazole, what we can learn from this, and how we can better manage a new drug's uncertain potential in the future. Medscape Psychiatry (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - May 27, 2016 Category: Psychiatry Tags: Psychiatry Commentary Source Type: news

Otsuka gets in on ReCor Medical’s Paradise renal denervation device
ReCor Medical said it landed a strategic investment from Japanese conglomerate Otsuka Pharmaceutical (TYO:4578) that will bring to Asia its Paradise renal denervation device for treating hypertension. Neither side is disclosing financial terms, but the deal calls for Otsuka to receive exclusive rights to pursue clinical trials, regulatory approval and commercialization of ReCor’s Paradise device in Japan, China, Korea and elsewhere in Asia. For starters, Otsuka will test Paradise in Japan to see if it can help patients with treatment-resistant hypertension. Paradise uses ultrasound energy to ablat...
Source: Mass Device - May 16, 2016 Category: Medical Equipment Authors: Mark Hollmer Tags: Clinical Trials Drug-Device Combinations Funding Roundup Pharmaceuticals Otsuka Pharmaceutical ReCor Medical Source Type: news

La FDA advierte de nuevos problemas de control de impulsos en relación con el medicamento para tratar la salud mental aripiprazol (Abilify, Abilify Maintena, Aristada)
[05/03/2016] La Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) advierte que se ha informado de deseos compulsivos o incontrolables de apostar, atracarse de comida, comprar y tener relaciones sexuales con el uso del fármaco antipsicótico aripiprazol (Abilify, Abilify Maintena, Aristada y sus versiones genéricas). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 9, 2016 Category: Drugs & Pharmacology Source Type: news

FDA Warns of Impulse-control Problems With Mental Health Drug
Compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 4, 2016 Category: Pharmaceuticals Source Type: news

FDA Warns of Rare Reactions to Abilify Medication
The Food and Drug Administration warned of rare cases in which patients taking the antipsychotic medication Abilify have experienced uncontrollable urges to gamble, binge eat, shop and engage in sex. (Source: WSJ.com: Health)
Source: WSJ.com: Health - May 4, 2016 Category: Pharmaceuticals Tags: FREE Source Type: news

FDA Warns of Compulsive Behaviors Associated with Antipsychotic Aripiprazole (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM The antipsychotic drug aripiprazole (marketed as Abilify, Abilify Maintena, and Aristada) is associated with compulsive or uncontrollable urges to gamble, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 3, 2016 Category: Primary Care Source Type: news

Aripiprazole linked to rare but serious compulsion problems
Rare but serious instances of impulse control problems have been reported in people taking the antipsychotic drug aripiprazole, according to a May 3 press release from the Food and Drug... (Source: Family Practice News)
Source: Family Practice News - May 3, 2016 Category: Primary Care Source Type: news

FDA Warning: Abilify Tied to Impulse Control Problems
(MedPage Today) -- In rare cases, may prompt "uncontrollable urges" (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - May 3, 2016 Category: Psychiatry Source Type: news

Impulse Control Problems Linked to Antipsychotic, FDA WarnsImpulse Control Problems Linked to Antipsychotic, FDA Warns
The FDA is warning of impulse control problems associated with the atypical antipsychotic aripiprazole. News Alerts (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - May 3, 2016 Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

FDA Drug Safety Communication: FDA warns about new impulse-control problems associated with mental health drug aripiprazole (Abilify, Abilify Maintena, Aristada)
[05-03-2016] The U.S. Food and Drug Administration (FDA) is warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Abilify, Abilify Maintena, Aristada, and generics). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 3, 2016 Category: Drugs & Pharmacology Source Type: news

MassDevice.com +5 | The top 5 medtech stories for April 27, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. FDA wants more from Proteus, Otsuka on ‘smart pill’ Otsuka Pharmaceutical and Proteus Digital Health said today that the FDA issued a complete response letter requesting more information from the companies for the c...
Source: Mass Device - April 27, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news

FDA declines to approve Proteus-Otsuka sensor-equipped pill, asks for more tests
The FDA declined to approve what would have been the first mass market drug to incorporate Proteus Digital Health's ingestible sensor. The drug, a collaboration between Proteus and Otsuka Pharmaceuticals, combines the Proteus system with the antipsychotic pharmaceutical Abilify. (Source: mobihealthnews)
Source: mobihealthnews - April 27, 2016 Category: Information Technology Source Type: news

FDA wants more from Proteus, Otsuka on ‘smart pill’
Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health  said today that the FDA issued a complete response letter requesting more information from the companies for the combination of the Proteus “smart pill” and Otsuka’s Abilify anti-depressant drug. The Proteus pill is designed to signal a wearable patch after it reaches the stomach, recording and time-stamping data from the pill and other patient metrics. The data can be relayed via Bluetooth to mobile devices and, with consent, to healthcare providers. The federal watchdog is requesting new data from the companies, including inform...
Source: Mass Device - April 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Drug-Device Combinations Food & Drug Administration (FDA) Otsuka Pharmaceutical Proteus Digital Health Source Type: news

Drug and behavioural therapy are both effective for tics in people with Tourette syndrome
There are effective drug and behavioural treatments for tics in children and young people with Tourette syndrome. Although most of the studies included in this review were small with risk of , the effects found were moderate to large and likely to be clinically meaningful. This NIHR funded and qualitative study found that habit reversal therapy, where people with Tourette's are taught to replace their tic with a less noticeable alternative, was effective. The drugs with the best balance of benefits and harms – risperidone, clonidine and aripiprazole – are those most commonly used in the UK. (Source: Current Awa...
Source: Current Awareness Service for Health (CASH) - April 7, 2016 Category: Consumer Health News Source Type: news

Facts You Should Know When Taking Abilify for...
Read about the use of Abilify for bipolar disorder and other health conditions, as well as information on its side effects and two black box warnings. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - March 28, 2016 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news